PARIS, Nov 24 (Reuters) - French biotech Vivalis and its British partner GlaxoSmithKline have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results